Bevacizumab for recurrent ependymoma.

Details

Serval ID
serval:BIB_EFDAE0A8E452
Type
Article: article from journal or magazin.
Collection
Publications
Title
Bevacizumab for recurrent ependymoma.
Journal
Neurology
Author(s)
Green R.M., Cloughesy T.F., Stupp R., DeAngelis L.M., Woyshner E.A., Ney D.E., Lassman A.B.
ISSN
1526-632X[electronic]
Publication state
Published
Issued date
2009
Volume
73
Number
20
Pages
1677-1680
Language
english
Abstract
BACKGROUND: Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies. Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy. At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor. In recurrent glioblastoma, encouraging responses with bevacizumab have been observed. METHODS: In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens. We determined radiographic response (Macdonald criteria), median time to progression (TTP), and median overall survival (OS; Kaplan-Meier method). RESULTS: There were 4 men and 4 women with a median age of 40 years (range, 20-65). Prior treatment included surgery (n = 8), RT (8), temozolomide (5), and carboplatin (4). Bevacizumab (5-15 mg/kg every 2-3 weeks) was administered alone (2) or concurrently with cytotoxic chemotherapy including irinotecan (3), carboplatin (2), or temozolomide (1). Six patients achieved a partial response (75%) and 1 remained stable for over 8 months. Median TTP was 6.4 months (95% confidence interval 1.4-7.4) and median OS was 9.4 months (95% confidence interval 7.0-not reached), with a median follow-up of 5.2 months among 5 surviving patients (63%). CONCLUSIONS: The radiographic response rate to bevacizumab-containing regimens is high. A prospective study is warranted.
Keywords
Phase-Ii, Radiotherapy, Temozolomide, Glioblastoma, Tumors
Pubmed
Web of science
Create date
02/12/2009 16:09
Last modification date
03/03/2018 22:35
Usage data